Your browser doesn't support javascript.
loading
Seroreactivity against lytic, latent and possible cross-reactive EBV antigens appears on average 10 years before MS induced preclinical neuroaxonal damage.
Jons, Daniel; Grut, Viktor; Bergström, Tomas; Zetterberg, Henrik; Biström, Martin; Gunnarsson, Martin; Vrethem, Magnus; Brenner, Nicole; Butt, Julia; Blennow, Kaj; Nilsson, Staffan; Kockum, Ingrid; Olsson, Tomas; Waterboer, Tim; Sundström, Peter; Andersen, Oluf.
Affiliation
  • Jons D; Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden daniel.jons@vgregion.se oluf.andersen@neuro.gu.se.
  • Grut V; Department of Clinical Science, Neurosciences, Umeå University, Umeå, Sweden.
  • Bergström T; Department of Infectious Diseases, Institute of Biomedicine, the Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden.
  • Zetterberg H; Department of Clinical Microbiology, Sahlgrenska University Hospital, Göteborg, Sweden.
  • Biström M; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden.
  • Gunnarsson M; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Vrethem M; Department of Clinical Science, Neurosciences, Umeå University, Umeå, Sweden.
  • Brenner N; Department of Neurology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
  • Butt J; Department of Neurology and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
  • Blennow K; Infections and Cancer Epidemiology, Infection, Inflammation and Cancer Research Program, German Cancer Research Center, Heidelberg, Germany.
  • Nilsson S; Infections and Cancer Epidemiology, Infection, Inflammation and Cancer Research Program, German Cancer Research Center, Heidelberg, Germany.
  • Kockum I; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden.
  • Olsson T; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Waterboer T; Mathematical Sciences, Chalmers University of Technology, Göteborg, Sweden.
  • Sundström P; Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden.
  • Andersen O; Department of Clinical Neuroscience, The Karolinska Neuroimmunology & Multiple Sclerosis Center, Center for Molecular Medicine, Karolinska Institute, Stockholm, Sweden.
J Neurol Neurosurg Psychiatry ; 95(4): 325-332, 2024 Mar 13.
Article in En | MEDLINE | ID: mdl-37802637
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Epstein-Barr Virus Infections / Multiple Sclerosis Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Neurol Neurosurg Psychiatry Year: 2024 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Epstein-Barr Virus Infections / Multiple Sclerosis Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Neurol Neurosurg Psychiatry Year: 2024 Document type: Article